Top

Joya Chandra, Ph.D.

Department of Pediatrics, Division of Pediatrics

About Dr. Joya Chandra

Dr. Chandra and her team carry out translational pediatric oncology research directed towards leukemia and brain tumor therapeutics with an emphasis on cell signaling, oxidative stress, epigenetics and cell death. Novel therapeutics, primarily small molecule inhibitors that target these pathways and have potential to improve treatment outcomes for pediatric leukemia and brain tumor patients, are a major focus of the lab. The impact of modifiable behaviors on treatment efficacy and treatment outcomes are another focus of the lab. Consistent with her work on modifiable behaviors, she leads clinical research related to diet and nutrition for pediatric cancer patients and survivors. On an institutional level, she serves as co-Director of the Center for Energy Balance in Cancer Prevention and Survivorship. She values training of the next generation of biomedical researchers highly and is a mentor to trainees of all levels. She served as the 2019-2020 President of the Graduate Faculty of the MD Anderson UT Health Graduate School of Biomedical Sciences. She has been recognized for excellence in education by her institutional peers (2009 & 2013 Faculty Educator of the Month Awards) and by graduate students (through the 2012 McGovern Outstanding Teacher Award), and by the UT System (2016 Regents Outstanding Teaching Award, and induction into the UT Academy of Health Science Education in 2020). On a national scale, she serves on DOD and NIH study sections that are education and career oriented. Former pre and postdoctoral trainees have received F31 and F32 NRSA grants as trainees in her lab. She currently co-leads two NIH training grants: a R25 grant for summer undergraduate researchers at MD Anderson as well as the CCTS TL1 grant for pre- and post-doctoral fellows at UT Health and MD Anderson.

Primary Appointment

Professor, Department of Pediatrics Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Graduate School of Biomedical Sciences, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), Houston, TX

Education & Training

Degree-Granting Education

1998	University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences, Houston, Texas, US, Ph.D. in Cancer Biology and Immunology
1993	Louisiana State University, Baton Rouge, Louisiana, US, B.S. Microbiology, Minors: English and Spanish

Postgraduate Training

2000-2002	Postdoctoral Fellowship, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota
1998-2000	Postdoctoral Fellowship, Division of Toxicology, Institute for Environmental Medicine, Karolinska Institute, Stockholm

Experience & Service

Faculty Academic Appointments

Associate Professor (Joint Appointment), Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas, 2013 - 2021

Associate Professor, Department of Pediatrics Research, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), Houston, Texas, 2008 - 2021

Assistant Professor, Department of Pediatrics Research, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), Houston, Texas, 2002 - 2008

Other Professional Positions

Postdoctoral Research Assistant, Institute for Environmental Medicine, Stockholm, Sweden, 1999 - 2000

Graduate Research Assistant, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1994 - 1998

Research Technician, Baylor Medical School, Houston, Texas, 1993 - 1994

Summer Research Intern, The University of Texas MD Anderson Cancer Center, Houston, Texas, 1991

Extramural Institutional Committee Activities

Committee Member, Promotion and Tenure Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Endowed Positions & Awards Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Committee Member, Chair Search, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 2024 - 2025

Committee Member, GME Mentoring Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Representative, CCSG Program Representative for Education, The University of Texas MD Anderson Cancer Center, 2024

Chair, Chair of Neuroscience Graduate Program 10 Year Review, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2023

Member, Institutional Cancer Survivorship Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present

Reviewer, Start-up package Proposals, Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 2023

Committee Member, Faculty Search, Department of Health Disparities, The University of Texas MD Anderson Cancer Center, 2023

Member, CCSG Representative for Cancer Genetics and Epigenetics Research Program Community Outreach and Engagement Group, The University of Texas MD Anderson Cancer Center, 2023 - Present

Proposal Reviewer, Proposal Reviewer for Limited Submissions, The University of Texas MD Anderson Cancer Center, 2023 - Present

Chair Search, Committee Member, Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, Paul E. Darlington Mentor Award Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Committee Member, Faculty Search, Health Disparities, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Past President, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2020 - 2021

Member, MDA GSBS Task Force, The University of Texas MD Anderson Cancer Center, 2020

Committee Member, Task Force on Research Transition from Phase I to II During Covid, The University of Texas MD Anderson Cancer Center, 2020

Committee Member, GSBS Task Force on Retaining Two Dean Model, The University of Texas MD Anderson Cancer Center, 2020

Chair Committee, GSBS Student Recommendations During Covid 19, The University of Texas MD Anderson Cancer Center, 2020

Faculty President, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2019 - 2020

Committee Member, Faculty Search, Department of Health Disparities, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Planning Committee, Energy Balance in Cancer Therapy Symposium, The University of Texas MD Anderson Cancer Center, 2019 - 2021

Faculty Vice President, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2018 - 2019

Committee Member, Faculty Search, Department of Health Disparities, The University of Texas MD Anderson Cancer Center, 2018 - 2020

Committee Member, Faculty Search, Department of Behavioral Sciences, The University of Texas MD Anderson Cancer Center, 2018 - 2020

Chair, GSBS Standing Comittee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2018 - 2019

Team Member, Energy Balance Team, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Therapeutics and Pharmacology Graduate Program, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2017 - 2024

Team Leader, Leukemia & Lymphoma Team, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 2017 - Present

Chair, Therapeutics and Pharmacology Graduate Program, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2017 - 2021

Member, Therapeutics and Pharmacology, Graduate School of Biomedical Sciences, 2017 - 2021

Team Member, AYA Team, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 2017 - Present

Director, Director of Research Training for Pediatric Hematology Oncology Fellows, The University of Texas MD Anderson Cancer Center, 2017 - 2022

Planning Committee, Cancer Survivorship and Energy Balance Research Symposium, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Committee Member, Faculty Search, Center for Energy Balance, The University of Texas MD Anderson Cancer Center, 2017 - 2019

Reviewer, Start-up package Proposals, Department of Lymphoma/Myeloma 2017, The University of Texas MD Anderson Cancer Center, 2017

Chair, Faculty Search , Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Organizer, Cancer Metabolism Symposium on Basic Cancer Research, The University of Texas MD Anderson Cancer Center, 2016 - 2017

Committee Member, Chair Search, Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 2016 - 2018

Member, Program Metamorphsis, The University of Texas MD Anderson Cancer Center, 2016 - Present

Committee Member, Faculty Search, Division of Pediatrics Health Outcomes Researcher, The University of Texas MD Anderson Cancer Center, 2015 - 2017

Member, Executive Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2015 - 2021

Member, Research Mentorship Committee, UT System-Wide, The University of Texas System, 2015 - 2016

Instructor, Mentoring Works Mini Course for Faculty, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2015 - 2016

Committee Member, Faculty Search, Center for Energy Balance, The University of Texas MD Anderson Cancer Center, 2014 - 2016

Committee Member, Faculty Search, Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, Patient-Reported Outcomes, Survey and Population Research (PROSPR) Shared Resource Advisory Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2015

Chair, The University of Texas MD Anderson Graduate Education Committee Academic Standards Subcommittee, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Member, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2012 - 2014

Member, The University of Texas MD Anderson Graduate Education Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2015

Member, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2011 - 2014

Member, Admissions Committee for Cancer Biology Program, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2011

Member, Experimental Therapeutics, Graduate School of Biomedical Sciences, 2010 - 2016

at-large, GSBS Standing Committee, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2010

Member, Executive Committee for Experimental Therapeutics Program, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Graduate School of Biomedical Sciences, 2010 - 2024

Chair, Awards Committee for Experimental Therapeutics Program, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Graduate School of Biomedical Sciences, 2010 - 2024

Member, Knudson Award Selection Committee for Outstanding Dissertation, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS), 2010 - 2012

Member, Cultural Competency, Children's Cancer Hospital UT MDACC, 2010

Member, Strategic planning for 5 year plan, Children's Cancer Hospital UT MDACC, 2010

Participant, SACS Site Visit, The University of Texas MD Anderson Cancer Center, 2010

Chair, Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2010 - 2016

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2009 - 2013

Member, Odyssey Fellowship Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2011

Member, Subcommittee on Faculty/Student Contracts, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences, Graduate School of Biomedical Sciences, 2007

Chair, International Affairs Subcommittee, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2010

Chair, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2006 - 2007

Chair, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences Student Affairs Committee, Graduate School of Biomedical Sciences, 2006 - 2007

Chair, GSBS Standing Committee, Graduate School of Biomedical Sciences, 2006 - Present

Member, GSBS Standing Committee, Graduate School of Biomedical Sciences, 2006 - 2007

Chair elect, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2006

Participant, SACS Site Visit, The University of Texas MD Anderson Cancer Center, 2005

Regular Member, Joint Student Affairs Council, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2005 - 2009

Vice President & President, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences Alumni Association, Graduate School of Biomedical Sciences, 2004 - 2006

Member, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences Student Affairs Committee, Graduate School of Biomedical Sciences, 2004 - 2007

Member, GSBS Standing Committee, Graduate School of Biomedical Sciences, 2004 - 2006

President, GSBS Alumni Association Steering Committee, Graduate School of Biomedical Sciences, 2004

Chair, Receptions Subcommittee, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Alternate, GSBS Standing Committee, Graduate School of Biomedical Sciences, 2003 - 2004

Regular Member, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2009

Member, Trainee Excellence Awards Subcommittee, The University of Texas MD Anderson Alumni and Faculty Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Member, GSBS Alumni Association Steering Committee, The University of Texas MD Anderson Cancer Center, 2003

Member, New Agents Working Group, The University of Texas MD Anderson Cancer Center, 2003 - 2008

Member, University of Texas Health Science Center at Houston Graduate School of Biomedical Sciences Alumni Association, The University of Texas MD Anderson Cancer Center, 2003 - 2008

Member, Cancer Biology, The University of Texas MD Anderson Cancer Center, 2002 - 2017

Editorial Activities

Senior Editor, Epidemiology and Prevention section, Cancer Research Communications (an AACR journal), 2021 - Present

Senior Editorial Board Member, Scientific Reports, 2020 - Present

Editorial Board Member, Pediatrics Medicine, 2019 - Present

Editorial Board Member, Leukemia & Lymphoma, 2017 - Present

Editorial Board Member, Scientific Reports, 2014 - 2020

Honors & Awards

2025	McMurray Outstanding Faculty Mentor Award, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences
2024	Faculty Leadership Academy Cohort 3, The University of Texas MD Anderson Cancer Center
2024	Paul E. Darlington Mentor Award
2024	William Randolph Hearst Foundation Faculty Achievement Award in Education, The University of Texas MD Anderson Cancer Center
2022	Paul E. Darlington Mentor Award
2022	President's Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2020	Highest Commendation for Service to the UTHSC GSBS, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2020	“Kenneth Shine” Academy for Health Science Education, The University of Texas System
2020	President's Recognition for Faculty Excellence in Education and Mentorship Advancement, The University of Texas MD Anderson Cancer Center
2020	Academy for Health Science Educators Cancer Center, The University of Texas MD Anderson
2017	President’s Recognition for Faculty Excellence in Education and Mentorship Advancement, The University of Texas MD Anderson
2016	Experimental Therapeutics Academic Program, Faculty Choice Award, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2016	Highest Commendation for Service to the UTHSC GSBS, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2016	University of Texas System Regents Outstanding Teaching Award, University of Texas System
2015	President's Recognition for Faculty Excellence, The University of Texas MD Anderson Cancer Center
2014	Texas Business Women’s Award, The University of Texas MD Anderson Cancer Center
2014 - 2015	Faculty Leadership Academy, The University of Texas MD Anderson Cancer Center
2013	Faculty Educator of the Month (April), The University of Texas MD Anderson Cancer Center
2012	John P. McGovern Outstanding Teacher Award, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2010	Reappointment to the UT GSBS Faculty with Commendation, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2009	Faculty Educator of the Month (May), The University of Texas MD Anderson Cancer Center
2004	Texas Federation of Business and Professional Women's Club Award, The University of Texas MD Anderson Cancer Center
2004	R.W. Butcher Award, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
2001	AACR-AFLAC Scholar-in-Training Award, American Association for Cancer Research
2001 - 2003	NIH NRSA Individual (F32) Training Grant, NIH
2000 - 2001	NIH NRSA Institutional (T32) Training Grant, NIH
2000	Wenner-Gren Foundation Fellowship for Visiting Scientists, Karolinska Institute
1999	Travel Scholarship for Seventh European Conference on Apoptosis, European Cell Death Organization
1999 - 2000	Karolinska Institute Fellowship for Visiting Scientists, Karolinska Institute
1997 - 1998	Andrew Sowell-Wade Huggins Endowed Scholarship, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)
1997	AACR-AFLAC Young Investigator Award, AACR
1997	M.D. Anderson Associates Travel Award, The University of Texas MD Anderson Cancer Center
1997	Texas Regional Immunology Conference James W. McLaughlin Oral Award, Texas Immunology Conference
1997 - 1998	American Legion Auxiliary Fellowship, UTHSC Graduate School of Biomedical Sciences
1996	Rhone-Poulenc Rorer Travel Award from American Association for Cancer Research (AACR), AACR
1996	John P. McGovern Award, The University of Texas MD Anderson UTHealth Houston Graduate School in Biomedical Sciences (GSBS)

Professional Memberships

American Society for Pharmacology and Experimental Therapeutics

2021 - Present

Association of Cancer Educators

2021 - Present

University of Texas Academy of Health Science Education Awards and Membership Committee

2020 - Present

Society for Neuro-Oncology

2017 - Present

American Society of Hematology

2003 - Present

Children's Oncology Group

2003 - Present

American Association for the Advancement of Science

1997 - Present

Women in Cancer Research

1997 - Present

American Association for Cancer Research

1996 - Present

Selected Presentations & Talks

Local Presentations

2025. Smoking Out Insights into AML. Invited. Houston, Texas, US.
2023. Optimizing Pediatric Cancer Treatment and Survivorship. Invited. Lucian Symposium. Houston, Texas, US.
2022. Striving to Improve Outcomes for Pediatric Cancer Patients and Survivors Through Modifiable Behaviors. Houston, Texas, US.
2022. 11th Annual Metabolism in Cancer Symposium. Conference. 11th Annual Metabolism in Cancer Symposium. Houston, TX, US.
2021. Enjoy Science Seminar Series. Conference. Enjoy Science Seminar Series. Houston, TX, US.
2019. Translational epigenetic research in pediatric brain and blood cancers. Invited. Translational epigenetic research in pediatric brain and blood cancers. Houston, TX, US.
2019. Striving to improve outcomes for pediatric brain and blood cancer patients. Invited. Striving to improve outcomes for pediatric brain and blood cancer patients, US.
2019. Leveraging epigenetic and redox vulnerabilities for translational research in pediatric brain and blood cancer. Invited. Leveraging epigenetic and redox vulnerabilities for translational research in pediatric brain and blood cancer. Houston, TX, US.
2018. Designing and delivering nutrition interventions in pediatric leukemia patients. Conference. Seventh Annual Metabolism in Cancer Symposium. Houston, TX, US.
2018. Optimizing nutrition of pediatric cancer patients and survivors. Conference. Children's Oncology Group. Dallas, TX, US.
2016. Promoting healthy lifestyles in pediatric cancer patients and survivors. Invited. Promoting healthy lifestyles in pediatric cancer patients and survivors. Houston, TX, US.
2015. Inhibiting histone deacetylation and histone methylation as a therapeutic strategy. Conference. Inhibiting histone deacetylation and histone methylation as a therapeutic strategy. Houston, TX, US.
2015. Targeting Oxidative Stress Emanating from Oncogenic Kinases. Invited. Targeting Oxidative Stress Emanating from Oncogenic Kinases. Houston, TX, US.
2015. Modulating Oxidative Stress in Cancer Cells. Invited. Modulating Oxidative Stress in Cancer Cells. Houston, TX, US.
2014. Understanding the redox environment of cancer cells to design and improve therapeutics. Invited. Understanding the redox environment of cancer cells to design and improve therapeutics. Houston, TX, US.
2014. Developmental Therapeutics for GBM Based on Epigenetic and Oxidative Stress Vulnerabilities. Conference. Developmental Therapeutics for GBM Based on Epigenetic and Oxidative Stress Vulnerabilities. Houston, TX, US.
2014. Exploiting the Redox Environment in Leukemia. Conference. Exploiting the Redox Environment in Leukemia. Houston, TX, US.
2014. The Optimizing Nutrition (ON) to Life Program at the MD Anderson Children's Cancer Hospital. Conference. The Optimizing Nutrition (ON) to Life Program at the MD Anderson Children's Cancer Hospital. Houston, TX, US.
2013. On to Life for Childhood Cancer Survivors: Designing Resources and Interventions for Optimizing Nutrition. Conference. On to Life for Childhood Cancer Survivors: Designing Resources and Interventions for Optimizing Nutrition. Houston, TX, US.
2013. Developing Therapeutic Strategies for GBM Based on Epigenetic and Oxidative Stress Vulnerabilities. Conference. Developing Therapeutic Strategies for GBM Based on Epigenetic and Oxidative Stress Vulnerabilities. Houston, TX, US.
2013. Barriers to obesity prevention among pediatric cancer patients and survivors: qualitative findings. Conference. Barriers to obesity prevention among pediatric cancer patients and survivors: qualitative findings. Houston, TX, US.
2013. Your toolbox as a summer student: literature review and methods. Conference. Your toolbox as a summer student: literature review and methods. Houston, TX, US.
2013. The ON (Optimizing Nutrition) Program at the Children's Cancer Hospital. Conference. The ON (Optimizing Nutrition) Program at the Children's Cancer Hospital. Houston, TX, US.
2011. ON (Optimizing Nutrition) to Life program at the Children's Cancer Hospital at MD Anderson. Conference. ON (Optimizing Nutrition) to Life program at the Children's Cancer Hospital at MD Anderson. Houston, TX, US.
2011. ON (Optimizing Nutrition) to Life Program. Conference. ON (Optimizing Nutrition) to Life Program. Houston, TX, US.
2011. ON to Life Program. Conference. ON to Life Program. Houston, TX, US.
2010. Oncogene-induced Oxidative Stress: Consequences on Leukemia Cell Signaling. Conference. Oncogene-induced Oxidative Stress: Consequences on Leukemia Cell Signaling. Houston, TX, US.
2009. Building Better Anti-Leukemia activity into HDACi Regimens for Leukemia. Conference. Building Better Anti-Leukemia activity into HDACi Regimens for Leukemia. Houston, TX, US.
2009. Regulating the Highs and the Lows of Oxidative Stress in Leukemias and Brain Tumors. Conference. Regulating the Highs and the Lows of Oxidative Stress in Leukemias and Brain Tumors. Houston, TX, US.
2009. Building Your CV. Conference. Building Your CV. Houston, TX, US.
2008. Part II: Therapeutic opportunities related to redox signaling in leukemia cells. Conference. Part II: Therapeutic opportunities related to redox signaling in leukemia cells. Houston, TX, US.
2008. Therapeutic Opportunities Related to Redox Signaling in Leukemia Cells. Conference. Therapeutic Opportunities Related to Redox Signaling in Leukemia Cells. Houston, TX, US.
2008. Therapeutic opportunities related to redox signaling in leukemia cells. Conference. Therapeutic opportunities related to redox signaling in leukemia cells. Houston, TX, US.
2008. Role of Oxidative Stress in the Mechanism of Action of Clinically Relevant Proteasome Inhibitors and HDAC Inhibitors. Conference. Role of Oxidative Stress in the Mechanism of Action of Clinically Relevant Proteasome Inhibitors and HDAC Inhibitors. Houston, TX, US.
2007. Building a better proteasome inhibitor: preclinical studies of NPI-0052. Conference. Building a better proteasome inhibitor: preclinical studies of NPI-0052. Houston, TX, US.
2006. Building Career Development Resources for Graduate Students. 2006 Faculty Retreat. Houston, Texas, US.
2006. Signaling consequences of ROS in leukemia. Conference. Signaling consequences of ROS in leukemia. Houston, TX, US.
2004. Therapeutic advantages of combining oxidative stress with signal transduction. Conference. Therapeutic advantages of combining oxidative stress with signal transduction. Houston, TX, US.
2004. Utilizing apoptotic effects of novel kinase inhibitors in leukemia cells. Conference. Utilizing apoptotic effects of novel kinase inhibitors in leukemia cells. Houston, TX, US.
2004. Surprising effects of biologically targeted therapies. Conference. Surprising effects of biologically targeted therapies. Houston, TX, US.
2004. Novel kinase inhibitors with surprising mechanisms of action. Conference. Novel kinase inhibitors with surprising mechanisms of action. Houston, TX, US.
2003. Adaphostin: a kinase inhibitor and more. Conference. Adaphostin: a kinase inhibitor and more. Houston, TX, US.

Regional Presentations

2023. Optimizing pediatric cancer treatment and survivorship. Conference. Optimizing pediatric cancer treatment and survivorship. Austin, TX, US.
2021. Designing and Delivering Nutrition Interventions for Pediatric Cancer Patients and Survivors. Invited. University of Texas at Austin, US.
2013. Epigenetics: More Than Your DNA. Conference. Epigenetics: More Than Your DNA. Austin, TX, US.
2012. Translating epigenetics to blood and brain cancers. Conference. Translating epigenetics to blood and brain cancers. Smithville, TX, US.
2011. Stress Management Lessons from Cancer Cells. Conference. Stress Management Lessons from Cancer Cells. Austin, TX, US.

National Presentations

2026. Emmy Noether Awards Luncheon. Invited. Community Foundation of Acadiana. Lafayette, Louisiana, US.
2026. Diet in Pediatric Cancer Patients and Survivors – Why Does This Matter?. Invited. St. Jude–VIVA Survivorship Series, US.
2025. Modifying Cancer Outcomes Using Modifiable Behaviors. Invited. Cancer Early Detection Advanced Research Center (CEDAR). Bend, Oregon, US.
2025. Translational potential for targeting epigenetic and kinase signaling vulnerabilities in pediatric high-grade gliomas. Invited. SBMT. Los Angeles, CA, US.
2024. Approaches to Studying the Impact of Nutrition on Cancer Outcomes. Invited. Food is Medicine in Oncology Care Symposium. Washington, DC, US.
2023. KUMC Cancer Biology Seminar. Kansas City, Kansas, US.
2020. Pharmacologic inhibition of lysine specific demethylase-1 (LSD) as an adjuvant immune - sensitization strategy in diffuse intrinsic pontine glioma (DIPG). Conference. Pharmacologic inhibition of lysine specific demethylase-1 (LSD) as an adjuvant immune - sensitization strategy in diffuse intrinsic pontine glioma (DIPG), US.
2019. Optimizing nutrition for pediatric cancer patients and survivors. Invited. Nutrition Center Seminar Series. Philadelphia, PA, US.
2018. Striving to improve outcomes for pediatric brain and blood cancer patients. Invited. Palo Alto, CA, US.
2015. Inhibition of heme oxygenase 1 decreases proliferation and re-sensitizes TKI resistant Flt3-ITD-positive AML cells. Conference. Inhibition of heme oxygenase 1 decreases proliferation and re-sensitizes TKI resistant Flt3-ITD-positive AML cells. Philadelphia, PA, US.
2015. Epigenetics in pediatric oncology. Invited. Epigenetics Symposium. Columbia, MO, US.
2015. The epigenetics of pediatric cancers. Conference. 11th Annual MU Life Sciences and Society Symposium. Columbia, MO, US.
2015. Targeting histone methylation and acetylation in acute lymphocytic leukemia. Conference. NCI. Rockville, MD, US.
2014. Cellular life and death decisions mediated by oxidative stress. Invited. Loyola University. Chicago, IL, US.
2014. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. Conference. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. San Diego, CA, US.
2014. The proteasome as a novel target in TKI resistant Flt3-ITD-positive AML. Conference. The proteasome as a novel target in TKI resistant Flt3-ITD-positive AML. San Diego, CA, US.
2013. Uncovering cardioprotective strategies for anthracycline therapy by analysis of redox and apoptotic effects. Conference. Uncovering cardioprotective strategies for anthracycline therapy by analysis of redox and apoptotic effects. New Orleans, LA, US.
2013. Unique apoptotic effects of panobinostat and marizomib in acute myeloid leukemia and bortezomib resident models. Conference. Unique apoptotic effects of panobinostat and marizomib in acute myeloid leukemia and bortezomib resident models. New Orleans, LA, US.
2013. Leveraging the cellular redox environment to optimize cancer therapies and minimize late effects. Invited. Center for Childhood Cancer and Blood Diseases. Columbus, OH, US.
2013. Being a postdoc in the land of noble. Invited. Center for Childhood Cancer and Blood Diseases. Columbus, OH, US.
2013. Comparison of kinetics and mechanism of cell death induction by the proteasome inhibitors bortezomib and marizomib in glioblastoma. Conference. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. Boston, MA, US.
2013. Mechanism of cell death induction by dual targeting of HDACs and lysine specific demethylase-1 in leukemias and brain tumors. Conference. AACR Special Conference on Chromatin and Epigenetics in Cancer. Atlanta, GA, US.
2013. Proteasome inhibitors in glioblastoma. Invited. Atlanta, GA, US.
2013. Effect of Histone Methyltransferase Inhibition in Acute Myeloid Leukemia Cell Lines. Conference. ASPHO Annual Meeting. Miami, FL, US.
2013. Comparison of Antiproliferative and Proapoptotic Effects of the Proteasome Inhibitors in Acute Myeloid Leukemia. Conference. Comparison of Antiproliferative and Proapoptotic Effects of the Proteasome Inhibitors in Acute Myeloid Leukemia. Miami, FL, US.
2013. The Antioxidant Heme Oxygenase 1 Promotes Proliferation and Survival of Fit3-ITD-positive AML. Conference. The Antioxidant Heme Oxygenase 1 Promotes Proliferation and Survival of Fit3-ITD-positive AML. Washington, DC, US.
2013. A role for p53 in the induction of apoptosis by combined inhibition of HDACs and KDM1A. Conference. Keystone Conference: Epigenetic Marks and Cancer Drugs. Santa Fe, NM, US.
2012. Inhibitors of histone deacetylation and demethylation synergize to induce cell death in acute leukemia cells. Conference. Inhibitors of histone deacetylation and demethylation synergize to induce cell death in acute leukemia cells. New Orleans, LA, US.
2012. A pilot study investigating the relationship between diet and oxidative stress in children receiving therapy for acute leukemia. Conference. A pilot study investigating the relationship between diet and oxidative stress in children receiving therapy for acute leukemia. New Orleans, LA, US.
2012. Oxidative stress analysis in peripheral blood mononuclear cells of pediatric leukemia undergoing chemotherapy: Correlations with dietary intake. Conference. Oxidative stress analysis in peripheral blood mononuclear cells of pediatric leukemia undergoing chemotherapy: Correlations with dietary intake. Chicago, IL, US.
2011. A pilot study investigating the relationship between diet and oxidative stress in infants receiving therapy for acute leukemia. Conference. A pilot study investigating the relationship between diet and oxidative stress in infants receiving therapy for acute leukemia. San Diego, CA, US.
2011. HDAC and LSD1 inhibitors synergize to induce cell death in acute leukemia cells. Conference. HDAC and LSD1 inhibitors synergize to induce cell death in acute leukemia cells. San Diego, CA, US.
2011. Dual inhibition of HDACs and KDM1A leads to the expression of genes involved in apoptosis. Conference. Dual inhibition of HDACs and KDM1A leads to the expression of genes involved in apoptosis. Garden Grove, CA, US.
2011. HDAC inhibitors, entinostat and vorinostat, synergize with adaphostin, a tyrphostin kinase inhibitor, increasing oxidative stress and apoptosis in leukemia cells. Conference. HDAC inhibitors, entinostat and vorinostat, synergize with adaphostin, a tyrphostin kinase inhibitor, increasing oxidative stress and apoptosis in leukemia cells. Washington, DC, US.
2010. Augmenting the Efficacy of HDAC Inhibitors. Conference. Augmenting the Efficacy of HDAC Inhibitors. Boston, MA, US.
2010. Requirement for the Src family kinase, Fyn, in proliferation of BCR-ABL1 transduced bone marrow and aneuploidy in CML. Conference. Requirement for the Src family kinase, Fyn, in proliferation of BCR-ABL1 transduced bone marrow and aneuploidy in CML. Washington, DC, US.
2010. Inhibition of LSD1 and HDACs causes synergistic cell death in glioblastoma cells. Conference. Inhibition of LSD1 and HDACs causes synergistic cell death in glioblastoma cells. Washington, DC, US.
2007. Leukemia cells thrive on oxidative stress: a mechanistic role for the Src family member, Fyn. Invited. Baltimore, MD, US.
2007. Incorporating measurements of oxidative stress into correlative studies for targeted therapies, POETIC Conference. Conference. POETIC Semi-Annual Meeting. Aspen, CO, US.
2007. The novel proteasome inhibitor, NPI-0052, synergizes with HDAC inhibitors to trigger apoptosis in leukemia cells. Conference. 97th Annual Meeting of the American Association for Cancer Research. Los Angeles, CA, US.
2006. Oxidatively stressing out leukemia cells. Invited. Palo Alto, CA, US.
2005. The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia cell lines and patient specimens. Conference. 47th Annual Meeting of American Society of Hematology. Atlanta, GA, US.
2005. Preclinical evaluation of NPI-0052, an irreversible proteasome inhibitor, in hematological malignancies. Conference. Winter SPORE Meeting for Hematological Malignancies. Duarte, CA, US.
2005. Effects of ROS production by adaphostin, a kinase inhibitor, on leukemia and myeloma cells. Conference. Winter SPORE Meeting for Hematological Malignancies. Duarte, CA, US.
2004. Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance. Conference. 12th SPORE Investigator's Workshop. Baltimore, MD, US.

International Presentations

2024. Integrating Food and Nutrition into Oncology Care Through Food is Medicine Interventions. Invited. World Congress of Epidemiology Conference, US.
2023. Preclinical and clinical strategies for treatment of pediatric malignancies incorporating epigenetic and metabolic vulnerabilities. Conference. Indian Science Congress, IN.
2021. Developing therapeutic strategies for pediatric oncology. Invited. San Juan, PR.
2018. Diet and exercise interventions for pediatric cancer patients, Oncology Nutrition Course. Conference. Academic Department of Nutrition and the Department of Human Reproduction, MX.
2018. Promoting healthy lifestyles in pediatric cancer patients and survivors , SIOP Nutrition Group. Conference. Promoting healthy lifestyles in pediatric cancer patients and survivors , SIOP Nutrition Group. Johannesburg, ZA.
2016. Promoting healthy lifestyles in pediatric cancer patients and survivors. Invited. Brisbane, AU.
2016. Epigenetically targeted strategies for brain tumor therapy. Conference. Neuro Oncology and Brain Tumor Conference, AU.
2015. Overcoming TKI resistance in chronic myeloid leukemia and EGFR mutant glioblastoma by targeting a Nox2-Egr1-Fyn pathway. Conference. Special Conference on Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic. Florence, IT.
2011. Targeting of Fyn induction by oxidative stress is an effective strategy for overcoming kinase inhibitor resistance in chronic myeloid leukemia and treating blast crisis. Conference. Targeting of Fyn induction by oxidative stress is an effective strategy for overcoming kinase inhibitor resistance in chronic myeloid leukemia and treating blast crisis. Gurgaon, Delhi, IN.
2011. Mechanisms that Determine the Efficacy of Two Proteasome Inhibitors, Bortezomib and Marizomib, in Glioblastoma. Conference. Mechanisms that Determine the Efficacy of Two Proteasome Inhibitors, Bortezomib and Marizomib, in Glioblastoma. Valencia, ES.
2010. Role of reactive oxygen species in Amrubicin's decreased cardiotoxicity. Conference. Role of reactive oxygen species in Amrubicin's decreased cardiotoxicity. Quebec, CA.
2010. Translational Cancer Research Using Novel Clinically Relevant Proteasome Inhibitors and Histone Deacetylase Inhibitors. Conference. Translational Cancer Research Using Novel Clinically Relevant Proteasome Inhibitors and Histone Deacetylase Inhibitors. Dubai, AE.
2009. Oncogene-induced oxidative stress: implications for cancer progression and drug resistance in leukemia. Conference. Oncogene-induced oxidative stress: implications for cancer progression and drug resistance in leukemia. Beijing, CN.
2008. Exploiting the Oxidative Environment of Leukemia Cells for Therapeutic Gain. Invited. San Juan, PR.
2008. Exploiting redox environments in leukemia cells for therapeutic value. DKFZ. Invited. Heidelberg, DE.
2008. Novel clinically relevant proteasome inhibitors and HDAC inhibitors. Conference. Ehrlich II, 2nd World Conference on Magic Bullets. Nurenberg, DE.
2008. A role for oxidative stress in the mechanism of action of novel biologically targeted therapies. Invited. Sao Paulo, BR.

Less

Grant & Contract Support

Date:	2026 - 2028
Title:	Assessing the Impact of Dietary Sucrose Consumption on Cardiotoxicity Induced by Cancer Treatment
Funding Source:	NIH/NCI
Role:	PI
ID:	R21 CA313919

Date:	2026 - 2031
Title:	Control of acute leukemia progression and therapy response through circadian and dietary modification
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA301709

Date:	2026 - 2028
Title:	Targeting the tumor microenvironment of DMG with LSD1 inhibition
Funding Source:	SnapGrant
Role:	Co-I
ID:	N/A

Date:	2025 - 2028
Title:	Leveraging inhibition of LSD1/KDM1A to augment immunotherapy of pediatric high grade glioma
Funding Source:	CPRIT
Role:	PI
ID:	RP260463

Date:	2025 - 2028
Title:	Feasibility Research for Enhancing Survivorship Health for Pediatric Oncology Patients (FRESH POP)
Funding Source:	NIH
Role:	PI
ID:	GRANT14372071

Date:	2025 - 2026
Title:	Digital culinary medicine: A scalable approach to improving diet quality among pediatric cancer survivors
Funding Source:	American Heart Association
Role:	Co-I
ID:	25FIMPG1486313

Date:	2025 - 2030
Title:	MD Anderson Summer Program in Cancer Research (SPCR)
Funding Source:	NIH/NCI
Role:	PI
ID:	R25CA181004-11

Date:	2025 - 2029
Title:	CHANGE (Cooking, Health, Nutrition, and Gardening Education) for Pediatric Leukemia Patients and Survivors
Funding Source:	CPRIT
Role:	PI
ID:	RP250283

Date:	2024 - 2029
Title:	CTSA Predoctoral T32 at the University of Texas Health Science Center at Houston
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	T32TR004905

Date:	2023 - 2023
Title:	Cook-Grow! A 16-week home cooking and gardening intervention for Cancer Survivors
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI
ID:	61939

Date:	2021 - 2025
Title:	Interrogation of the KDM1A-IL18 axis in pediatric high-grade glioma
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH2110728

Date:	2021 - 2026
Title:	Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse
Funding Source:	NIH/NCI
Role:	PI
ID:	5R01NS122857

Date:	2020 - 2023
Title:	Defining mechanisms of cigarette smoking-induced TKI resistance in Ph+ ALL
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI
ID:	59764

Date:	2020 - 2022
Title:	Combinatorial epigenetics strategies for GBM to enhance immune sensitization and overcome radiation resistance
Funding Source:	NIH/NCI
Role:	Principal Investigator of Developmental Research
ID:	P50 CA 127001

Date:	2020 - 2022
Title:	Defining and leveraging nutritional and circadian dependencies to augment acute leukemia treatment
Funding Source:	NIH/NCI
Role:	PI
ID:	1R21NR019532-01

Date:	2020 - 2024
Title:	NRSA Training Core for the Center for Clinical and Translational Sciences ( CCTS )
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	5TL1TR003169

Date:	2020 - 2022
Title:	Evaluation of Novel Dually Targeted Kinase Inhibitors for Therapy of Adult and Pediatric High-Grade Glioma
Funding Source:	NIH/NCI
Role:	PI
ID:	R33NS111058-02

Date:	2020 - 2024
Title:	Doxorubicin-induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP200381

Date:	2019 - 2024
Title:	Efficacy of NutriCare Plus a Medically Tailored Meal Intervention on Optimizing Nutritional Status, Reducing Treatment-Related Adverse Effects, and Improving Quality of Life among Lung Cancer Patients
Funding Source:	Bristol-Myers Squibb Foundation
Role:	Co-PI

Date:	2019 - 2022
Title:	SPORE in Brain Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P50CA127001-15

Date:	2019 - 2023
Title:	Evaluating mechanisms of and preventing increased myeloid leukemia risk and progression from smoking
Funding Source:	MDACC
Role:	Principal Investigator-MDACC
ID:	Tobacco Pilot Project

Date:	2019 - 2020
Title:	Measuring the Clinical and Psychosocial Impact of the CHEF Teaching Kitchen in Pediatric Cancer Survivors
Funding Source:	Children’s Hospital of San Antonio Culinary Health Education for Families (CHEF) Clinical Research
Role:	Co-PI
ID:	AWD00004451

Date:	2018 - 2020
Title:	Energy Balance Strategies for Decreasing Chemotherapy-Induced Cardiotoxicity
Funding Source:	Alex’s Lemonade Stand
Role:	Co-PI

Date:	2017 - 2019
Title:	Targeting PLK1 as a Common Mechanism in Ph-like ALL
Funding Source:	Alex’s Lemonade Stand Foundation
Role:	PI
ID:	AWD00000377

Date:	2016 - 2018
Title:	HDAC6 expression, upregulation and immunomodulatory effects in myeloma and lymphoma models
Funding Source:	Sponsored Research Agreement, Karus Pharmaceuticals
Role:	PI
ID:	52614

Date:	2015 - 2017
Title:	Defining and targeting epigenetic regulators of metabolism in Leukemia patients and survivors
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI
ID:	51075

Date:	2015 - 2019
Title:	Preclinical evaluation of a novel combinatory epigenetics based therapy for glioblastoma
Funding Source:	NIH/NINDS
Role:	PI
ID:	R21 NS093387

Date:	2015 - 2019
Title:	Epigenetics in Medulloblastoma Development and Therapeutics
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP150301

Date:	2014 - 2016
Title:	Manipulating metabolic pathways to enhance HDAC inhibitor efficacy in refractory multiple myeloma
Funding Source:	University of Texas MD Anderson Cancer Center SPORE in Multiple Myeloma
Role:	PI
ID:	P50 CA142509

Date:	2014 - 2014
Title:	Biomarkers for Clinical Trials in Multiple Myeloma Evaluating Carfilzomib and Panobinostat
Funding Source:	Novartis Pharmaceuticals
Role:	CO-I

Date:	2013 - 2014
Title:	A Community Based Cancer Prevention Study in Obese Children and Families
Funding Source:	Racing for Cancer Foundation
Role:	PI

Date:	2013 - 2016
Title:	New Therapies For Glioblastoma
Funding Source:	Thomas Scott Family Foundation
Role:	PI

Date:	2013 - 2015
Title:	Leukemia SPORE to MDACC
Funding Source:	NIH/NCI
Role:	Developmental Research Project Recipient
ID:	P50 CA100632

Date:	2012 - 2013
Title:	A Community Based Nutrition and Physical Activity Intervention
Funding Source:	Luci Baines Johnson Foundation
Role:	PI

Date:	2012 - 2015
Title:	The role of HO-1 in FLT3-ITD positive AML proliferation and drug resistance
Funding Source:	NIH/NCI
Role:	Mentor
ID:	F32CA171905

Date:	2012 - 2013
Title:	Targeting Epigenetic Alterations in Acute Leukemias
Funding Source:	NIH/NCI
Role:	PI

Date:	2012 - 2018
Title:	Efficacy and Safety of Combina
Funding Source:	Novartis Pharmaceuticals Corporation
Role:	PI

Date:	2011 - 2014
Title:	Dual LSD1 and HDAC Inhibition for Cancer Therapy
Funding Source:	NIH/NCI
Role:	Mentor
ID:	F32 CA150610

Date:	2011 - 2013
Title:	ON to Life Program
Funding Source:	Farrah Fawcett Foundation
Role:	PI

Date:	2011 - 2012
Title:	Discovering New Treatment Strategies for Glioblastoma
Funding Source:	TeamConnor Cancer Foundation
Role:	PI

Date:	2010 - 2012
Title:	Combined LSD1 and HDAC Inhibition for Glioblastoma Therapy
Funding Source:	NIH/NCI Brain Cancer SPORE to MDACC
Role:	Developmental Research Project Recipient
ID:	P50 CA127001-03

Date:	2010 - 2015
Title:	Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
Funding Source:	NIH/NCI
Role:	CO-I
ID:	1 R01 CA151533

Date:	2009 - 2011
Title:	Pilot study measuring caloric intake and oxidative stress as predictors of clinical outcome in infants with cancer
Funding Source:	The Gerber Foundation
Role:	PI

Date:	2009 - 2011
Title:	ARRA Diversity Supplement to Role of Redox Dependent Signaling in Leukemia
Funding Source:	NIH/NCI
Role:	PI
ID:	R01 CA115811-03S1

Date:	2009 - 2011
Title:	Measuring redox effects of the novel anthracycline, amrubicin, in cancer cell line models
Funding Source:	Pharmion Corporation
Role:	PI

Date:	2007 - 2008
Title:	Philanthropic Donation
Funding Source:	Pharmacyclics
Role:	PI

Date:	2007 - 2013
Title:	Role of redox dependent signaling in leukemia
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA115811

Date:	2006 - 2007
Title:	Philanthropic Donation
Funding Source:	Nereus Pharmaceuticals
Role:	PI

Date:	2006 - 2009
Title:	Apoptosis by inhibition of B subunits of the proteasome
Funding Source:	NIH/NCI
Role:	Mentor
ID:	F31 CA123645

Date:	2006 - 2007
Title:	Role of redox regulatory enzymes in bcr/abl positive leukemias
Funding Source:	Children's Leukemia Research Association
Role:	PI

Date:	2005 - 2006
Title:	Manipulation of the redox environment by biologically targeted agents in leukemia cells
Funding Source:	Texas Business and Professional Women's Clubs
Role:	PI

Date:	2004 - 2006
Title:	Career Development Award, Mechanism of action and basis for selectivity of adaphostin, a tyrphostin inhibitor
Funding Source:	NIH/NCI Leukemia SPORE to MDACC
Role:	PI
ID:	5P50CA100632-03 (Issa)

Date:	2004 - 2005
Title:	Various Donors Fund for Brain Tumor Research
Funding Source:	CancerSucks Foundation
Role:	PI

Date:	2003 - 2004
Title:	Mechanism of action of adaphostin, a novel kinase inhibitor, in pediatric p190 bcr/abl positive leukemic cells
Funding Source:	Children's Oncology Group Young Investigator Award
Role:	PI

Date:	2003 - 2005
Title:	Mechanism of action of adaphostin, a novel kinase inhibitor, in p190 bcr/abl positive leukemic cells
Funding Source:	The University of Texas MD Anderson Cancer Center Institutional Research Grant
Role:	PI

Date:	2002 - 2009
Title:	Faculty Recruitment/Start-up funds
Funding Source:	The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2001 - 2003
Title:	Mechanism of action of a novel tyrosine kinase inhibitor
Funding Source:	NIH/NCI
Role:	PI
ID:	NRSA F32 CA-93055

Selected Publications

Peer-Reviewed Articles

Rivero-Jimenz, M, Poche, A, Haushalter, K, Hudson, E, Larson, D, Nikah, K, Garcia, M, Roth, M, Davis, J, Chandra J. Cook Grow!: Insights from a Pilot Study on a Virtual Cooking, Gardening, and Nutrition Education Program for Childhood Cancer Survivors and their Families. Journal of Cancer Letters, 2026.
Zhang S, Jin Y, Jia Z, Xia X, Li Y, Wang Q, Wang, Jing, Wang, Jian, Chandra J, Friedman G, Li S. Fgl2-knockout tumor cells serve as a vaccine inducing long-duration brain-resident memory T cells that reject subsequent intracranial tumor cell challenges. Cancer Letters, 2025. e-Pub 2025. PMID: 41380903.
Stitzlein L, Nam D, Hernandez F, Patel K, Poche A, Huaxian M, Impelman K, Gumin J, Wang H, Wang J, Gadd S, Zaky W, Becher O, Dudley R, Lang F, Sareddy G, Chandra J. Combined inhibition of lysine-specific demethylase 1 and kinase signaling as a preclinical treatment strategy in glioblastoma. Neuro-Oncology Advances 7(1), 2025. e-Pub 2025. PMID: 41497449.
Owens C, Keaver L, Chandiramani D, McCann J, Cohen M.K., Chandra J, Presley C, Bauman J, Pai L, Daugherty S, Smith J, Spees C, Zhang F. F.. Medically tailored meals in lung cancer care: patient experiences from the NutriCare Clinical Trial. Journal of Cancer Survivorship, 2025. e-Pub 2025. PMID: 40643889.
Propst C, Sucholeiki R, Chandra J, Livingston J, Roth M, Hong D, George G. Diet in adolescent and young adult patients with cancer and cancer survivors: a scoping review. Supportive Care in Cancer, 2025. e-Pub 2025. PMID: 40411574.
Stitzlein LM, Baig M, Chandra J, McGovern SL, Paulino A, Ketonen L, Khatua SK, Zaky W. Phase I Study of Vorinostat and Temsirolimus in Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma. Pediatric Blood & Cancer, 2025. e-Pub 2025. PMID: 40000388.
Rodriguez M, Fekry B, Murphy B, Figueroa M, Cheng T, Raber M, Wartenberg L, Bell D, Triche L, Crawford K, Ma H, Allton K, Ahmed R, Tran J, Ranieri C, Konopleva M, Barton M, Nunez C, Eckel-Mahan K, Chandra J. Feasible diet and circadian interventions reduce in vivo progression of FLT3-ITD positive acute myeloid leukemia. Cancer Medicine, 2024. e-Pub 2024. PMID: 38334474.
Hudson E, M Burgermaster, Isis S, Jeans M, Vandyousefi S, Landry M, Seguin-Fowler R, Chandra J, Davis J. School-based intervention impacts availability of vegetables and beverages in participants' homes. Frontiers in Nutrition, 2023. e-Pub 2023. PMID: 38162521.
Figueroa M, Ma H, Alfayez M, Morales-Mantilla DE, Wang F, Lu Y, Estecio M, King KY, Kleinerman ES, Moghaddam SJ, Daver NG, Andreeff M, Konopleva MY, DiNardo CD, Chandra J. Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv, 2023. e-Pub 2023. PMID: 37486624.
Sharma M, Barravecchia I, Teis R, Cruz J, Mumby R, Ziemke EK, Espinoza CE, Krishnamoorthy V, Magnuson B, Ljungman M, Koschmann C, Chandra J, Whitehead CE, Sebolt-Leopold JS, Galban S. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. Mol Cancer Ther, 2023. e-Pub 2023. PMID: 37723046.
Jeyabal P, Bhagat A, Wang F, Roth M, Livingston JA, Gilchrist SC, Banchs J, Hildebrandt MAT, Chandra J, Deswal A, Koutroumpakis E, Wang J, Daw NC, Honey TA, Kleinerman ES. Circulating microRNAs and cytokines as prognostic biomarkers for doxorubicin-induced cardiac injury and for evaluating the effectiveness of an exercise intervention. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37651264.
Jeans MR, Landry MJ, Vandyousefi S, Hudson EA, Burgermaster M, Bray MS, Chandra J, Davis JN. Effects of a School-Based Gardening, Cooking, and Nutrition Cluster Randomized Controlled Trial on Unprocessed and Ultra-Processed Food Consumption. J Nutr 153(7):2073-2084, 2023. e-Pub 2023. PMID: 37116658.
Wooten SV, Amini B, Livingston JA, Hildebrandt MAT, Chandra J, Gilchrist SC, Roth M, Kleinerman E. Poor Sit-to-Stand Performance in Adolescent and Young Adult Patients with Sarcoma. J Adolesc Young Adult Oncol, 2023. e-Pub 2023. PMID: 37155195.
Stitzlein LM, Gangadharan A, Walsh LM, Nam D, Espejo AB, Singh MM, Patel KH, Lu Y, Su X, Ezhilarasan R, Gumin J, Singh S, Sulman E, Lang FF, Chandra J. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles. Front Neurol 14:1112207, 2023. e-Pub 2023. PMID: 37082446.
Garcia MB, Schadler KL, Chandra J, Clinton SK, Courneya KS, Cruz-Monserrate Z, Daniel CR, Dannenberg AJ, Demark-Wahnefried W, Dewhirst MW, Fabian CJ, Hursting SD, Irwin ML, Iyengar NM, McQuade JL, Schmitz KH, Basen-Engquist K. Translating energy balance research from the bench to the clinic to the community: Parallel animal-human studies in cancer. CA Cancer J Clin 73(4):425-442, 2023. e-Pub 2023. PMID: 36825928.
Wooten SV, Roth M, Livingston JA, Hildebrandt MAT, Chandra J, Amini B, Kleinerman ES, Gilchrist SC. Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients. J Adolesc Young Adult Oncol 11(3):320-322, 2022. e-Pub 2022. PMID: 34388045.
Raber M, Costigan M, Chandra J, Basen-Engquist K. Cooking After Cancer: the Structure and Implementation of a Community-Based Cooking Program for Cancer Survivors. J Cancer Educ 37(3):539-545, 2022. e-Pub 2022. PMID: 32754833.
Kannan S, Irwin ME, Herbrich SM, Cheng T, Patterson LL, Aitken MJL, Bhalla K, You MJ, Konopleva M, Zweidler-McKay PA, Chandra J. Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy. Antioxidants (Basel) 11(4), 2022. e-Pub 2022. PMID: 35453402.
Wang F, Chandra J, Kleinerman ES. Exercise Intervention Decreases Acute and Late Doxorubicin-Induced Cardiotoxicity. Cancer Med 10(21):7572-7584, 2021. e-Pub 2021. PMID: 34523825.
Bailey CP, Wang R, Figueroa M, Zhang S, Wang L, Chandra J. Computational immune infiltration analysis of pediatric high-grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Comput Syst Oncol 1(3), 2021. e-Pub 2021. PMID: 34723252.
Wartenburg L, Raber M, Chandra J. Unique features of a web-based nutrition website for childhood cancer populations : availability, features and content. Journal of Medical Internet Research 13(23):9, 2021. e-Pub 2021. PMID: 32176517.
van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, ESJM DB, Horton TM, Kornblau SM. Loss of H3K27M methylation identifies poor outcomes in adult-onset acute leukemia. Clinical Epigenetics 13(21), 2021. e-Pub 2021. PMID: 33509276.
Cheng T, Kiser KJ, Grasse LM, Iles LR, Bartholomeusz G, Samaniego F, Orlowski R, Chandra J. Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. Cancer Drug Resistance 4(4), 2021. e-Pub 2021. PMID: 34888496.
Swartz MC, Teague AK, Wells SJ, Honey T, Fu M, Mahadeo KM, Kabiri LS, Chandra J, Moody K, Schadler K. Feasibility and Acceptability Findings of an Energy Balance Data Repository of Children, Adolescents, and Young Adults with Cancer. J Clin Med 9(9), 2020. e-Pub 2020. PMID: 32899945.
Bailey CP, Figueroa M, Gangadharan A, Lee DA, Chandra J. Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol 11:2196, 2020. e-Pub 2020. PMID: 33042135.
Raber M, Baranowski T, Crawford K, Sharma SV, Schick V, Markham C, Jia W, Sun M, Steinman E, Chandra J. The Healthy Cooking Index: Nutrition Optimizing Home Food Preparation Practices across Multiple Data Collection Methods. J Acad Nutr Diet 120(7):1119-1132, 2020. e-Pub 2020. PMID: 32280056.
Murphy BR, Raber MP, Crawford KD, Grasse L, Wartenberg L, Wu J, Dibaj SS, Chandra J. High Rates of Obesity at Presentation Persist into Survivorship across Childhood Cancer Types. Child Obes 16(4):250–257, 2020. e-Pub 2020. PMID: 32176517.
Raber M, Crawford K, Baranowski T, Sharma SV, Schick V, Markham C, Roth M, Wakefield CE, Chandra J. Meal planning values impacted by the cancer experience in families with school-aged survivors-a qualitative exploration and recommendations for intervention development. Support Care Cancer 28(3):1305-1313, 2020. e-Pub 2020. PMID: 31243584.
Bailey CP, Figueroa M, Gangadharan A, Yang Y, Romero MM, Kennis BA, Yadavilli S, Henry V, Collier T, Monje M, Lee DA, Wang L, Nazarian J, Gopalakrishnan V, Zaky W, Becher OJ, Chandra J. Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG). Neuro Oncol, 2020. e-Pub 2020. PMID: 32166329.
Raber M, Basen-Engquist K, Moran NE, Chandra J. The Healthy Cooking Index does not Predict the Carotenoid Content of Home-Cooked Meals. Nutrients 12(2), 2020. e-Pub 2020. PMID: 32092844.
Raber M, Crawford K, Baranowski T, Sharma SV, Schick V, Markham C, Roth M, Chandra J. Exploring food preparation practices in families with and without school-aged childhood cancer survivors. Public Health Nutr 23(3):410-415, 2020. e-Pub 2020. PMID: 31538553.
Cohen J, Collins L, Gregerson L, Chandra J, Cohn RJ. Nutritional concerns of survivors of childhood cancer: A "First World" perspective. Pediatr Blood Cancer:e28193, 2020. e-Pub 2020. PMID: 31994836.
Morales-Mantilla DE, Huang X, Erice P, Porter P, Zhang Y, Figueroa M, Chandra J, King KY, Kheradmand F, Rodríguez A. Cigarette Smoke Exposure in Mice using a Whole-Body Inhalation System. J Vis Exp(164), 2020. e-Pub 2020. PMID: 33165327.
Raber M, Wu J, Donnella H, Knouse P, Pise M, Munsell M, Liu D, Chandra J. Cellular Oxidative Stress in Pediatric Leukemia and Lymphoma Patients Undergoing Treatment Is Associated with Protein Consumption. Nutrients 12(1), 2019. e-Pub 2019. PMID: 31892127.
Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Mol Cancer Ther 18(9):1615-1627, 2019. e-Pub 2019. PMID: 31227645.
Herbrich SM, Kannan S, Nolo RM, Hornbaker M, Chandra J, Zweidler-McKay PA. Characterization of TRKA signaling in acute myeloid leukemia. Oncotarget 9(53):30092-30105, 2018. e-Pub 2018. PMID: 30046390.
Eterovic AK, Maher OM, Chandra J, Chen K, Huse J, Zaky W. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing. J Natl Compr Canc Netw 16(6):683-691, 2018. e-Pub 2018. PMID: 29891519.
Wang F, Iskra B, Kleinerman E, Alvarez-Florez C, Andrews T, Shaw A, Chandra J, Schadler K, Aune GJ. Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity. J Pediatr Hematol Oncol 40(3):208-215, 2018. e-Pub 2018. PMID: 29557918.
Raber M, Huynh TN, Crawford K, Kim S, Chandra J. Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health, 2018. e-Pub 2018. PMID: 29532214.
Rivera-Del Valle N, Cheng T, Irwin ME, Donnella H, Singh MM, Chandra J. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations. Cancer Chemother Pharmacol 81(3):483-495, 2018. e-Pub 2018. PMID: 29313067.
Zaky W, Manton C, Miller CP, Khatua S, Gopalakrishnan V, Chandra J. The ubiquitin-proteasome pathway in adult and pediatric brain tumors: biological insights and therapeutic opportunities. Cancer Metastasis Rev 36(4):617-633, 2017. e-Pub 2017. PMID: 29071526.
Raber M, Crawford K, Chandra J. Healthy cooking classes at a children's cancer hospital and patient/survivor summer camps: initial reactions and feasibility. Public Health Nutr:1-7, 2017. e-Pub 2017. PMID: 28463101.
Raber M, Chandra J, Upadhyaya M, Schick V, Strong LL, Durand C, Sharma S. An evidence-based conceptual framework of healthy cooking. Prev Med Rep 4:23-8, 2016. e-Pub 2016. PMID: 27413657.
Li R, Donnella H, Knouse P, Raber M, Crawford K, Swartz MC, Wu J, Liu D, Chandra J. A randomized nutrition counseling intervention in pediatric leukemia patients receiving steroids results in reduced caloric intake. Pediatr Blood Cancer, 2016. e-Pub 2016. PMID: 27615542.
Swartz MC, Basen-Engquist KM, Markham C, Lyons EJ, Cox M, Chandra J, Ater JL, Askins MA, Scheurer ME, Lupo PJ, Hill R, Murray J, Chan W, Swank PR. Psychometric Analysis of the Three-Factor Eating Questionnaire-R18V2 in Adolescent and Young Adult-Aged Central Nervous System Tumor Survivors. J Adolesc Young Adult Oncol 5(3):278-285, 2016. e-Pub 2016. PMID: 27042872.
Luan J, Chu Z, Chandra J, Zhang P. Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer. Curr Protein Pept Sci 17(5):455 - 462, 2016. e-Pub 2016. PMID: 26796303.
Manton CA, Johnson B, Singh M, Bailey CP, Bouchier-Hayes L, Chandra J. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Sci Rep 6:18953, 2016. e-Pub 2016. PMID: 26804704.
Fulbright JM, Egas-Bejar DE, Huh WW, Chandra J. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy. Cancer Chemother Pharmacol 76(6):1297-307, 2015. e-Pub 2015. PMID: 26515054.
Irwin M, Johnson B, Manshouri R, Amin H, Chandra J. A NOX2/Egr-1/Fyn pathway delineates new targets for TKI resistant malignancies. Oncotarget 6(27):23631-46, 2015. e-Pub 2015. PMID: 26136341.
Li R, Raber M, Mejia L, Domenech M, Brewster A, Swartz MC, Strong L, Chandra J. Development and Feasibility of a Culturally Sensitive Cooking and Physical Activity Program Designed for Obese Hispanic Families. Infant, Child, & Adolescent Nutrition 20(10):1-8, 2015. e-Pub 2015.
Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leukemia Research 39(3):371-9, 2015. e-Pub 2015. PMID: 25612941.
Singh MM, Johnson B, Venkatarayan A, Flores ER, Zhang J, Su X, Barton M, Lang F, Chandra J. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro-Oncology, 2015. e-Pub 2015. PMID: 25795306.
Braun FK, Mathur R, Sehgal L, Wilkie-Grantham R, Chandra J, Berkova Z, Samaniego F. Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis. PLOS ONE 10(3), 2015. e-Pub 2015. PMID: 25738497.
Li R, Raber M, Chandra J. Developing a healthy web-based cookbook for pediatric cancer patients and survivors: rational and methods. JMIR Research Protocols 4(1), 2015. e-Pub 2015. PMID: 25840596.
Santa Maria D, Swartz M, Markham C, Chandra J, McCurdy S, Basen-Engquist K. Exploring Parental Factors Related to Weight Management in Survivors of Childhood CNS Tumors. Journal of Pediatric Oncology Nursing 31(2):89-84, 2014. e-Pub 2014. PMID: 24608701.
Papke CL, Cao J, Kwartler CS, Villamizar C, Byanova KL, Lim SM, Sreenivasappa H, Fischer G, Pham J, Rees M, Wang M, Chaponnier C, Gabbiani G, Khakoo AY, Chandra J, Trache A, Zimmer W, Milewicz DM. Smooth muscle hyperplasia due to loss of smooth muscle a-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-B. Hum Mol Genet 22(15):3123-31, 2013. e-Pub 2013. PMID: 23591991.
Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Hughes DP, Chandra J. Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Plos One 8(8):e70608, 2013. e-Pub 2013. PMID: 23936456.
Beltran A, Li R, Ater J, Baranowski J, Buday R, Thompson D, Chandra J, Baranowski T. Adapting A Videogame to the Needs to Pediatric Cancer Patients and Survivors. Games for Health Journal 2(4):213-221, 2013. e-Pub 2013. PMID: 26192225.
Badr H, Chandra J, Paxton RJ, Ater JL, Urbauer D, Cruz CS, Demark-Wahnefried W. Health-related quality of life, lifestyle behaviors, and intervention preferences of survivors of childhood cancer. Journal of Cancer Survivorship 7(4):523-34, 2013. e-Pub 2013. PMID: 23749663.
Singh MM, Howard A, Irwin ME, Gao Y, Lu X, Multani A, Chandra J. Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia. Plos One 7(12):e51611, 2012. e-Pub 2012. PMID: 23284724.
Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J. Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia. Cancer 118(13):3433-45, 2012. e-Pub 2012. PMID: 22139798.
Miller CP, Manton C, Hale R, DeBose L, Macherla VR, Potts BC, Palladino MA, and Chandra J. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs. Chemico-Biological Interactions 194(2011):58-68, 2011. e-Pub 2011. PMID: 21864512.
Singh M, Manton C, Bhat K, W-W T, Aldape K, Barton M, Chandra J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-Oncology 13(8):894-903, 2011. e-Pub 2011. PMID: 21653597.
Hu J, Liu X, Hughes D, Esteva FJ, Liu B, Chandra J, Li S. Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis. PLoS ONE(8):e23270, 2011. e-Pub 2011. PMID: 21853100.
Shi P, Chandra J, Sun X, Gergely M, Cortes JE, Garcia-Manero G, Arlinghaus RB, Lai R, Amin HM. Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukemia cells. J Cell Mol Med 14(6B):1777-92, 2010. e-Pub 2010. PMID: 19508387.
Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, Steggerda S, Wheler J, Balasubramanian S, Chandra J. PCI-24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol, 2010. e-Pub 2010. PMID: 20145726.
Howard AN, Bridges KA, Meyn RE, Chandra J. ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress. Cancer Chemother Pharmacol 65(1):41-54, 2009. e-Pub 2009. PMID: 19404643.
Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic Properties of Metronomic Topotecan in Ovarian Carcinoma. Cancer Biol Ther 8(16):1596-1603, 2009. e-Pub 2009. PMID: 19738426.
Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic Activity of the Src Family Kinase Inhibitor Dasatinib and Oxaliplatin in Colon Carcinoma Cells is Mediated by Oxidative Stress. Cancer Res 69(9):3842-9, 2009. e-Pub 2009. PMID: 19383922.
Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 113(18):4289-99, 2009. e-Pub 2009. PMID: 19182209.
Gao Y, Howard A, Ban K, Chandra J. Oxidative stress promotes transcriptional upregulation of Fyn in BCR-ABL1 expressing cells. J Biol Chem 284(11):7114-25, 2009. e-Pub 2009. PMID: 19131339.
Gao S, Mobley A, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells. Leukemia Research 32(5):771-80, 2008. e-Pub 2008. PMID: 18031811.
Ban K, Gao Y, Amin HM, Howard A, Miller C, Lin Q, Leng X, Munsell M, Bar-Eli M, Arlinghaus RB, Chandra J. BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood 111(5):2904-8, 2008. e-Pub 2008. PMID: 18180382.
Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino M, Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS -dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 110(1):267-277, 2007. e-Pub 2007. PMID: 17356134.
Long J, Manchandia T, Ban K, Gao S, Miller C, Chandra J. Adaphostin cytoxicity in glioblastoma cells is ROS-dependent and is accompanied by upregulation of heme oxygenase-1. Cancer Chemother & Pharmaco 59(4):527-535, 2007. e-Pub 2007. PMID: 16924499.
Orsolic N, Golemovic M, Quintas-Cardama A, Scappini B, Manshouri T, Chandra J, Basic I, Giles F, Kantarjian H, Verstovsek S. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Science 97(9):952-960, 2006. e-Pub 2006. PMID: 16822295.
Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Molecular Cancer Therapeutics 5(7):1836-1843, 2006. e-Pub 2006. PMID: 16891470.
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood 107:2501-2506, 2006. e-Pub 2006. PMID: 16291594.
Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 102:4512-4519, 2003. e-Pub 2003. PMID: 12920036.
Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, Kaufmann SH. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem 278:47326-47339, 2003. e-Pub 2003. PMID: 12963734.
Kagan VE, Gleiss B, Tyurina YY, Tyurin VA, Elenstrom-Magnusson C, Liu SX, Serinkan FB, Arroyo A, Chandra J, Orrenius S, Fadeel B. A role for oxidative stress in apoptosis: oxidation and externalization of phosphatidylserine is required for macrophage clearance of cells undergoing Fas-mediated apoptosis. J Immunol 169(1):487-499, 2002. e-Pub 2002. PMID: 12077280.
Nutt LK, Chandra J, Pataer A, Fang B, Roth JA, Swisher SG, O'Neil RG, McConkey DJ. Bax-mediated Ca2+ mobilization promotes cytochrome c release during apoptosis. J Biol Chem 277(23):20301-8, 2002. e-Pub 2002. PMID: 11909872.
Lotfi K, Mansson E, Chandra J, Wang Y, Xu D, Knaust E, Spasokoukotskaja T, Liliemark E, Eriksson S, Albertioni F. Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br J Haematol 113(2):339-346, 2002. e-Pub 2002. PMID: 11380397.
Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood 99(2):655-663, 2002. e-Pub 2002. PMID: 11781251.
Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99(2):664-671, 2002. e-Pub 2002. PMID: 11781252.
Lundberg M, Johansson C, Chandra J, Enoksson M, Jacobsson G, Ljung J, Johansson M, Holmgren A. Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms. J Biol Chem 276(28):26269-26275, 2001. e-Pub 2001. PMID: 11297543.
Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S. Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes 50 Suppl 1:S44-S47, 2001. e-Pub 2001. PMID: 11272200.
Chandra J, Yang SN, Kohler M, Zaitsev S, Juntti-Berggren L, Berggren PO, Zhivotovsky B, Orrenius S. Effects of serum from patients with type 1 diabetes on primary cerebellar granule cells. Diabetes 50 Suppl 1:S77-S81, 2001. e-Pub 2001. PMID: 11272207.
Multani AS, Ozen M, Narayan S, Kumar V, Chandra J, McConkey DJ, Newman RA, Pathak S. Caspase-dependent apoptosis induced by telomere cleavage and TRF2 loss. Neoplasia 2(4):339-345, 2000. e-Pub 2000. PMID: 11005568.
Fadeel B, Gleiss B, Hogstrand K, Chandra J, Wiedmer T, Sims PJ, Henter JI, Orrenius S, Samali A. Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression. Biochem Biophys Res Commun 266(2):504-511, 1999. e-Pub 1999. PMID: 10600532.
Bold RJ, Chandra J, McConkey DJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6:279-285, 1999. e-Pub 1999. PMID: 10340887.
Multani AS, Chandra J, McConkey J, Sen S, Cabral TF, Pathak S. Cell death in paclitaxel-dependent Chinese hamster ovary cells is initiated by the loss of telomeric DNA repeats. Oncol Res 11:455-460, 1999. e-Pub 1999. PMID: 10850886.
Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92:4220-4429, 1998. e-Pub 1998. PMID: 9834227.
Bouvet M, Bold RJ, Lee J, Evans DB, Abbruzzese JL, Chiao PJ, McConkey DJ, Chandra J, Chada S, Fang B, Roth JA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol 5:681-688, 1998. e-Pub 1998. PMID: 9869513.
Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem 272(49):3113-3117, 1997. e-Pub 1997. PMID: 9388264.
Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemic lymphocytes. Blood 90(9):3673-3681, 1997. e-Pub 1997. PMID: 9345052.
McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 156(7):2624-2630, 1996. e-Pub 1996. PMID: 8786328.

Invited Articles

Cheng T, Chandra J. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. Drugs of Today--Prous Thomson Reuters 51(8):491-504, 2015. e-Pub 2015. PMID: 26380387.
Irwin ME, Rivera-Del Valle N, Chandra J. Redox Control of Leukemia: From Molecular Mechanisms to Therapeutic Opportunities. Antioxidants & Redox Signaling 18(11):1349-83, 2013. e-Pub 2013. PMID: 22900756.
Dent SY, Chandra J. The lasting influence of LSD1 in the blood, 2013. e-Pub 2013. PMID: 23795303.
Co-Reyes E, Li R, Huh W, Chandra J. Malnutrition and Obesity in Pediatric Cancer Patients: Causes, Consequences, and Interventions. Pediatric Blood & Cancer 59(7):1160-1167, 2012. e-Pub 2012. PMID: 22948929.
Potts BC, Albitar MX, Anderson KC, Baritaki S, Berkers C, Bonavida B, Chandra J, Chauhan, D, Cusack Jr JC, Fenical W, Ghobrial IM, Groll M, Jensen PR, Lam KS, Lloyd GK, McBride W, McConkey DJ, Miller C, Neuteboom STC, Ovaa H, Pajonk F, Roccaro AM, Sloss CM, Spear MA, Valash E, Younes A and Palladine MA. Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials. Current Cancer Drug Targets 11(3):254-284, 2011. e-Pub 2011. PMID: 21247382.
Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, (corresponding author) CJ. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inibitors. Journal of Biomedicine and Biotechnology, 2011. e-Pub 2011. PMID: 21765634.
Fulbright JM, Huh W, Anderson P, Chandra J. Can anthracycline therapy for pediatric malignancies be less cardiotoxic?. Current Oncology Reports 12(6):411-9, 2010. e-Pub 2010. PMID: 20820959.
Chandra J. Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies. Antioxid Redox Signal 11(5):1123-1127, 2009. e-Pub 2009. PMID: 19018667.
Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol 13:453-462, 2001. e-Pub 2001. PMID: 11673685.
Robertson JD, Chandra J, Gogvadze V, Orrenius S. Biological reactive intermediates and mechanisms of cell death. Adv Exp Med Biol 500:1-10, 2001. e-Pub 2001. PMID: 11764918.
McConkey DJ, Chandra J. Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia. Leuk Lymphoma 33:421-431, 1999. e-Pub 1999. PMID: 10342570.

Review Articles

Sarkar S, Stitzlein L, Chandra J. Impact of electronic cigarettes on pediatric, adolescent and young adult leukemia patients. Pediatric Medicine, 2024. e-Pub 2024. PMID: 38616981.
Stitzlein L, Adams J, Stizlein E, Dudley R, Chandra J. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks. Journal of Experimental & Clinical Cancer Research, 2024. e-Pub 2024. PMID: 38183103.
Sun Y, Bailey CP, Sadighi Z, Zaky W, Chandra J. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities. J Neurooncol, 2020. e-Pub 2020. PMID: 32504402.
Bailey CP, Figueroa M, Mohiuddin S, Zaky W, Chandra J. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG). Bioengineering (Basel) 5(4), 2018. e-Pub 2018. PMID: 30340362.
Schadler KL, Kleinerman ES, Chandra J. Diet and exercise interventions for pediatric cancer patients during therapy: tipping the scales for better outcomes. Pediatr Res 83(1-1):50-56, 2018. e-Pub 2018. PMID: 29068433.
Raber M, Swartz MC, Maria DS, O'Connor T, Baranowski T, Li R, Chandra J. Parental involvement in exercise and diet interventions for childhood cancer survivors: A systematic review. Pediatr Res, 2016. e-Pub 2016. PMID: 27064243.
Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29(3-4):323-333, 2000. e-Pub 2000. PMID: 11035261.

Abstracts

Alqahtani S, Figueroa M, Ma H, Chandra J. Investigating the Impact of Smoking Traditional and E-Cigarettes on Acute Myeloid Leukemia Progression. American Society of Hematology 142(1), 2023. e-Pub 2023.
Stitzlein L, Adams J, Luetzen M, Singh M, Su X, Lu Y, Ezhilarasan R, Gumin J, Sulman E, Lang F, Monje M, Chandra J. Efficacy of LSD1-Directed Agents is Enhanced with Kinase Signaling Inhibition in Glioblastoma Stem Cells. Journal of Pharmacology and Experimental Theraputics 385(S 3), 2023. e-Pub 2023.
Rodriguez M, Figueroa M, Murphy B, Cheng T, Fekry B, Allton K, Barton M, Konopleva M, Mahan K, Chandra J. Effects of diet composition and timing on treatment for FLT3 positive acute myeloid leukemia. Cancer Research 82(12), 2022. e-Pub 2022.
Stitzlein L, Luetzen M, McCabe C, Khosla M, Singh M, Su X, Lu Y, Gumin J, Lang F, Whitehead C, Sebolt-Leopold J, Chandra J. Efficacy of EGFR/PI3K signaling inhibition is enhanced with LSD1 inhibition in glioblastoma stem cell models. Cancer Research 82(12), 2022. e-Pub 2022.
Stitzlein L, Gangadharan A, Grasse L, Espejo A, Singh M, Lu Y, Ezhilarasan R, Gumin J, Sulman E, Lang F, Chandra J. Evaluation of in vitro and in vivo efficacy of pharmacological lysine-specific demethylase 1 inhibitors in glioblastoma stem cell models. FASEB, 2022. e-Pub 2022.
Irwin M, Chandra J. Inhibition of heme oxygenase 1 decreases proliferation and re-sensitizes TKI resistant Flt3-ITD-positive AML cells. Cancer Research 75(15), 2015. e-Pub 2015.
Irwin ME, Manshouri R, Johnson B, Amin HM, Chandra J. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. Cancer Research 74(19), 2014. e-Pub 2014.
Egas-Bejar D, Fulbright J, Corrales-Medina F, Irwin ME, Johnson B, Chandra J. Uncovering cardioprotective strategies for anthracycline therapy by analysis of redox and apoptotic effects. American Society of Hematology 122(21), 2013. e-Pub 2013.
Manton CA, Johnson B, Bouchier-Hayes L, Chandra J. Comparison of kinetics and mechanism of cell death induction by the proteasome inhibitors bortezomib and marizomib in glioblastoma. Cancer Research 12(11), 2013. e-Pub 2013.
Li R, Beltran A, Baranowski J, Thompson DI, Chandra J, Baranowski T. Barriers to obesity prevention among pediatric cancer patients and survivors: qualitative findings. Journal of Academy of Nutrition and Dietetics 113(9), 2013. e-Pub 2013.
Singh MM, Donnella H, Ramirez L, Chandra J. Mechanism of cell death induction by dual targeting of HDACs and lysine specific demethylase-1 in leukemias and brain tumors. Cancer Research 73(13), 2013. e-Pub 2013.
Knouse P, Mise M, Furr J, Li R, Bell D, Triche L, Palla S, Chandra J. A pilot study investigating the relationship between diet and oxidative stress in children receiving therapy for acute leukemia. Blood 118(21):4228, 2012. e-Pub 2012.
Chandra J, Knouse P, Li R, Bell D, Triche L, Palla S. Oxidative stress analysis in peripheral blood mononuclear cells of pediatric leukemia undergoing chemotherapy: Correlations with dietary intake. Cancer Research 72(8), 2012. e-Pub 2012.
Knouse P, Pise M, Furr J, Li R, Bell D, Triche L, Palla S, Chandra J. A pilot study investigating the relationship between diet and oxidative stress in infants receiving therapy for acute leukemia. Blood 118(21), 2011. e-Pub 2011.
Ramirez L, Singh M, Chandra J. HDAC and LSD1 inhibitors synergize to induce cell death in acute leukemia cells. Blood 118(21), 2011. e-Pub 2011.
Lu X, Gao Y, Singh M, Chandra J. Requirement for the Src family kinase, Fyn, in proliferation of BCR-ABL1 transduced bone marrow and aneuploidy in CML. Cancer Research 70(8), 2010. e-Pub 2010.
Singh MM, Manton C, Tsai W, Barton* W, Chandra J. Inhibition of LSD1 and HDACs causes synergistic cell death in glioblastoma cells. Cancer Research 70(8), 2010. e-Pub 2010.
Gao S, Lu X, Sirisawad M, Steggerda S, Balasubramanian S, Chandra J. PCI-24781, a novel hydroxamic acid HDAC inhibitor, raises intracellular levels of reactive oxygen species, induces apoptosis and inhibits NFkB in leukemia models. International Journal of Cell Biology, 2010. e-Pub 2010. PMID: 20145726.
Fulbright JM, Chandra J. Limiting Anthracycline-Induced Cardiotoxicity Using Amrubicin in Leukemia System. Blood 114(22), 2009. e-Pub 2009.
Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 and oxidant dependent hyper-acetylation of histone-H3 by the novel proteasome inhibitor NPI-0052. Cancer Research 69(9), 2009. e-Pub 2009.
Rivera-Del Valle N, Gao S, Lu X, Sirisawad M, Steggerda S, Balasubramanian S, Wheler J, Chandra J. PCI-24781, a novel hydroxamic acid HDAC inhibitor, induces apoptosis and histone acetylation in a caspase-8 dependent manner in leukemia cells. Cancer Research 69(9), 2009. e-Pub 2009.
Howard AN, Gao Y, Chandra J. Overexpression of constitutively active Fyn kinase affects growth and cell cycle in CML. Cancer Research 69(9), 2009. e-Pub 2009.
Hale R, Miller CP, Manam RR, Macherla VR, Palladino M, Potts B, Chandra J. Analysis of reactive oxygen species (ROS) generation and caspase-8 activation by analogs of proteasome inhibitor NPI-0052. Cancer Research 69(9), 2009. e-Pub 2009.
Miller CP, Palladino M, Chandra J. Overlapping functional activities of proteasome inhibitor, NPI-0052, and HDAC inhibitors contribute to synergistic cytotoxicity in leukemia cells. Cancer Research, 2008. e-Pub 2008.
Howard A, Gao Y, Ban K, Chandra J. Upregulation of Fyn in CML occurs through ROS-dependent transcription by Sp1 and Egr-1. Cancer Research 68(9), 2008. e-Pub 2008.
Howard A, Ban K, Gao Y, Arlinghaus R, Amin H, Chandra J. Heightened Fyn expression in CML is BCR/ABL-and oxidant-dependent. Cancer Research 67(9), 2007. e-Pub 2007.
Nelson LD, Siwak DR, Lu Y, Mills GB, Miller C, Chandra J, Hughes DPM. ErbB signaling promotes BCR-Abl expression and modulates multiple signaling pathways as assessed by high-throughput reverse-phase protein array. Cancer Research 67(9), 2007. e-Pub 2007.
Gao S, Boklan J, Chandra J. Synergistic cytotoxic effects of MS-275 and 5-azacytidine in leukemia cells. Cancer Research 67(9), 2007. e-Pub 2007.
Nelson L, Siwak D, Lu Y, Miller C, Chandra J, Hughes D. ErbB signaling promotes BCR-Abl expression and modulates multiple signaling pathways as assessed by high-throughput reverse-phase protein array. Blood 108(11), 2006. e-Pub 2006.
Chandra J, Amin HM, Howard A, Miller CP. Fyn upregulation is a novel ROS-dependent mechanism controlling CML growth, progression and imatinib resistance. Blood 108(11), 2006. e-Pub 2006.
Miller C, Ban K, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia lymphoma cell lines and patient specimens. Blood 106(11), 2005. e-Pub 2005.
Hughes D, Tracy J, Lee K, Zhang P, Estrov Z, Chandra J. ERBB Expression in Philadelphia Chromosome-Positive ALL as a Potential Therapeutic Target. Blood 106(11), 2005. e-Pub 2005.
Miller C, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. Reactive oxygen species generation and caspase 8 activation are required for apoptosis induction by a novel proteasome inhibitor in lymphoid cells. Cancer Research 65(9), 2005. e-Pub 2005.
Miller C, Dujka M, Ruiz S, Neuteboom S, Palladino M, McConkey M, Chandra J. Apoptosis induction by a novel proteasome inhibitor relies on oxidant production and caspase-8 activation in lymphoid but not myeloid cells, 2005. e-Pub 2005.
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance. Blood, 2004. e-Pub 2004.
Miller C, Dujka, M, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. Distinct effects of proteasome inhibition by a novel inhibitor in lymphoid cells. European Journal of Cancer Supplements 2(8):171, 2004. e-Pub 2004.
Chandra J, Mow B, Weisberg E, Griffin J, Sausville E, Kaufmann SH. Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on leukemic cells in vitro. Blood, 2001. e-Pub 2001. PMID: 11781252.
Chandra J, Yang SN, Kohler M, Zaitsev S, Juntti-Berggren L, Berggren PO, Zhivotovsky B, Orrenius S. Effects of serum from patients with insulin-dependent diabetes mellitus on primary cerebellar granule cells. Diabetes, 2001. e-Pub 2001. PMID: 11272207.
Chandra J, Amin HM, Howard A, Miller CP. Fyn upregulation is a novel ROS-dependent mechanism controlling CML growth, progression and imatinib resistance. American Society of Hematology 2005 Annual Meeting.
Hughes D, Tracy J, Lee K, Zhang P, Estrov Z, Chandra J. ERBB Expression in Philadelphia Chromosome-Positive ALL as a Potential Therapeutic Target. American Society of Hematology 2005 Annual Meeting.
Howard A, Ban K, Gao Y, Arlinghaus R, Amin H, Chandra J. Heightened Fyn expression in CML is BCR/ABL-and oxidant-dependent. American Association for Cancer Research 2007 Annual Meeting.
Chandra J, Howard A, Jensen K, Meyn R. Induction of oxidative stress and glutathone depletion by ABT-737, a novel small molecular inhibitor of Bcl-2, contributes to cytotoxicty in leukemia cells. American Society of Hematology 2007 Annual Meeting.
Gao S, Boklan J, Chandra J. Synergistic cytotoxic effects of MS-275 and 5-azacytidine in leukemia cells. American Association for Cancer Research 2007 Annual Meeting.
Nelson LD, Siwak DR, Lu Y, Mills GB, Miller C, Chandra J, Hughes DPM. ErbB signaling promotes BCR-Abl expression and modulates multiple signaling pathways as assessed by high-throughput reverse-phase protein array. American Association for Cancer Research 2007 Annual Meeting.
Miller CP, Chandra J. The novel proteasome inhibitor, NPI-0052, synergizes with HDAC inhibitors to trigger apoptosis in leukemia cells. American Association for Cancer Research 2007 Annual Meeting.
Gao S, Miller C, Boklan J, Chandra J. Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemia cells. American Society of Hematology 2007 Annual Meeting.
Miller CP, Palladino M, Chandra J. Overlapping functional activities of proteasome inhibitor, NPI-0052, and HDAC inhibitors contribute to synergistic cytotoxicity in leukemia cells. American Association of Cancer Research Annual Meeting 2008.
Gao S, Lu X, Sirisawad M, Steggerda S, Balasubramanian S, Chandra J. PCI-24781, a novel hydroxamic acid HDAC inhibitor, raises intracellular levels of reactive oxygen species, induces apoptosis and inhibits NFkB in leukemia models. American Association of Cancer Research 2008 Annual Meeting.
Howard A, Gao Y, Ban K, Chandra J. Upregulation of Fyn in CML occurs through ROS-dependent transcription by Sp1 and Egr-1. American Association of Cancer Research 2008 Annual Meeting.
Howard AN, Gao Y, Chandra J. Overexpression of constitutively active Fyn kinase affects growth and cell cycle in CML. American Association of Cancer Research 2009 Annual Meeting.
Rivera-Del Valle N, Gao S, Lu X, Sirisawad M, Steggerda S, Balasubramanian S, Wheler J, Chandra J. PCI-24781, a novel hydroxamic acid HDAC inhibitor, induces apoptosis and histone acetylation in a caspase-8 dependent manner in leukemia cells. American Association of Cancer Research 2009 Annual Meeting.
Hale R, Miller CP, Manam RR, Macherla VR, Palladino M, Potts B, Chandra J. Analysis of reactive oxygen species (ROS) generation and caspase-8 activation by analogs of proteasome inhibitor NPI-0052. American Association of Cancer Research 2009 Annual Meeting.
Fulbright JM, Chandra J. Limiting Anthracycline-Induced Cardiotoxicity Using Amrubicin in Leukemia System. American Society of Hematology 2009 Annual Meeting.
Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 and oxidant dependent hyper-acetylation of histone-H3 by the novel proteasome inhibitor NPI-0052. American Association of Cancer Research 2009 Annual Meeting.
Miller CP, Keating MJ, Wierda WG, Palladino M, Chandra J. Histone-H3 hyper-acetylation by a novel proteasome inhibitor, NPI-0052, is mediated by caspase-8 activation and reactive oxygen species. Keystone Symposia on Targeted Cancer Therapies.
Rivera-Del Valle N, Sausville E, Kaufmann S, Chandra J. Adaphostin, a tyrphostin kinase inhibitor, increases the cytotoxic effect of HDAC inhibitors, SNDX/MS-275 and vorinostat, in leukemia cells. Keystone Symposia on Targeted Cancer Therapies.
Lu X, Gao Y, Singh M, Chandra J. Requirement for the Src family kinase, Fyn, in proliferation of BCR-ABL1 transduced bone marrow and aneuploidy in CML. American Association of Cancer Research 2010 Annual Meeting.
Fulbright J, Hamir A, Lu X, Chandra J. Role of Reactive oxygen species in Amrubicin's decreased cardiotoxicity and Leukema cell Cytotoxicity. The American Society of Pediatric Hematology Oncology 2010 Annual Meeting.
Singh MM, Manton C, Tsai W, Barton W, Chandra J. Inhibition of LSD1 and HDACs causes synergistic cell death in glioblastoma cells. American Association of Cancer Research 2010 Annual Meeting.
Knouse P, Pise M, Furr J, Li R, Bell D, Triche L, Palla S, Chandra J. A pilot study investigating the relationship between diet and oxidative stress in infants receiving therapy for acute leukemia. American Society of Hematology 2011 Annual Meeting and Exhibition.
Manton C, Chandra J. Mechanisms that Determine the Efficacy of Two Proteasome Inhibitors, Bortezomib and Marizomib, in Glioblastoma. EMBO Workshop on Intracellular Proteolysis and Cancer 2011.
Irwin M, Singh M, Chandra J. Targeting of Fyn Induction by oxidative stress is an effective strategy for overcoming kinase inhibitor resistance in chronic myeloid leukemia and treating blast crisis. American Association of Cancer Research 2011 International Conference.
Singh M, Chandra J. Dual inhibition of HDACs and KDM1A leads to the expression of genes involved in apoptosis. Society for Neurooncology 2011 Annual Meeting.
Rivera-Del Valle N, Chandra J. HDAC inhibitors, entinostat and vorinostat, synergize with adaphostin, a tyrphostin kinase inhibitor, increasing oxidative stress and apoptosis in leukemia cells. The Society of Toxicology 2011 Annual Meeting.
Ramirez L, Singh M, Chandra J. HDAC and LSD1 inhibitors synergize to induce cell death in acute leukemia cells. American Society of Hematology 2011 Annual Meeting and Exhibition.
Ramirez L, Singh M, Chandra J. Inhibitors of histone deacetylation and demethylation synergize to induce cell death in acute leukemia cells. American Society of Pediatric Hematology/Oncology 2012 meeting.
Chandra J. Oxidative stress analysis in peripheral blood mononuclear cells of pediatric leukemia undergoing chemotherapy: Correlations with dietary intake. American Association of Cancer Research 2012 Annual Meeting.
Corrales-Medina F, Egas-Bejar D, Irwin ME, Rivera N, Chandra J. Comparison of Antiproliferative and Proapoptotic Effects of the Proteasome Inhibitors in Acute Myeloid Leukemia. American Society of Pediatric Hematology/Oncology 2013 Annual Meeting.
Singh MM, Donnella H, Ramirez L, Chandra J. Mechanism of cell death induction by dual targeting of HDACs and lysine specific demethylase-1 in leukemias and brain tumors. American Association of Cancer Research Special Conference on Chromatin and Epigenetics 2013.
Egas-Bejar D, Fulbright J, Corrales-Medina F, Irwin ME, Johnson B, Chandra J. Uncovering cardioprotective strategies for anthracycline therapy by analysis of redox and apoptotic effects. American Society of Hematology 2013 Annual Meeting.
Irwin ME, Chandra J. The Antioxidant Heme Oxygenase 1 Promotes Proliferation and Survival of Fit3-ITD-positive AML. American Association of Cancer Research 2013 Annual Meeting.
Singh MM, Zhang J, Xiaoping S, Barton M, Chandra J. A role for p53 in the induction of apoptosis by combined inhibition of HDACs and KDM1A. Keystone Conference 2013: Epigenetic Marks and Cancer Drugs.
Li R, Beltran A, Baranowski J, Thompson DI, Chandra J, Baranowski T. Barriers to obesity prevention among pediatric cancer patients and survivors: qualitative findings. Food and Nutrition Conference Academy of Nutrition and Dietetics 2013.
Corrales-Medina F, Egas-Behar D, Manton C, Johnson B, Irwin ME, Orlowski RZ, Chandra J. Unique apoptotic effects of panobinostat and marizomib in acute myeloid leukemia and bortezomib resident models. American Society of Hematology 2013 Annual Meeting.
Egas-Bejar D, Corrales-Medina, Irwin ME, Rivera N, Chandra J. Effect of Histone Methyltransferase Inhibition in Acute Myeloid Leukemia Cell Lines. American Society of Pediatric Hematology/Oncology 2013 Annual Meeting.
Manton CA, Johnson B, Bouchier-Hayes L, Chandra J. Comparison of kinetics and mechanism of cell death induction by the proteasome inhibitors bortezomib and marizomib in glioblastoma. AACR-NCI-EOTRC Conference on Molecular Targets and Cancer Therapeutics.
Irwin ME, Manshouri R, Johnson B, Amin HM, Chandra J. Targeting Egr-1 is an effective strategy for overcoming kinase inhibitor resistance in CML. American Association of Cancer Research 2014 Annual Meeting.
Chandra J. The proteasome as a novel target in TKI resistant-Flt3-ITD-positive AML. American Association of Cancer Research 2014 Annual Meeting.
Irwin M, Chandra J. Inhibition of heme oxygenase 1 decreases proliferation and re-sensitizes TKI resistant Flt3-ITD-positive AML cells. American Association of Cancer Research 2015 Annual Meeting.
Irwin M, Johnson B, Chandra J. Overcoming TKI resistance in chronic myeloid leukemia and EGFR mutant glioblastoma by targeting a Nox2-Egr1-Fyn pathway.
Jack Adams, Lea Stitzlein, Melissa Singh, Xiaoping Su, Yue Lu, Michelle Monje, Christopher Whitehead, Judith Sebolt-Leopold, Chandra J. Co-inhibition of kinase signaling pathways and epigenetic regulators overcomes compensatory effects in pediatric high-grade gliomas. Society for Neuro-Oncology 2022 Annual Meeting.
Kumar S, Chandra J, Grote D, Cattaneo R, Kaufmann S, Fielding A. Bcl-2 over-expression results in decreased measles virus mediated cytotoxicity in lymphoma cell lines. American Society of Hematology 2022 Annual Meeting.
Stitzlein L, Adams J, Luetzen M, Singh M, Su X, Lu Y, Ezhilarasan R, Gumin J, Sulman E, Lang F, Monje M, Chandra J. Efficacy of kinase signaling inhibition is enhanced with LSD1 inhibition in high-grade glioma. Therapeutics and Pharmacology Graduate Program Annual Retreat.
Stitzlein, L.M, Gangadharan, A, Grasse, L, Espejo, A, Singh, M, Lu, Y, Ezhilarasan, R, Gumin, J, Sulman, E, Lang, F, Chandra J. Evaluation of in vitro and in vivo efficacy of pharmacological lysine-specific demethylase 1 (LSD1) inhibitors in glioblastoma stem cell models. Experimental Biology.
Stitzlein, L.M, Luetzen, M, McCabe, C, Khosla, M, Singh, M, Su, X, Lu, Y, Gumin, J, Lang, F, Whitehead, C, Sebolt-Leopold, J, Chandra J. Efficacy of EGFR/PI3K signaling inhibition is enhanced with LSD1 inhibition in glioblastoma stem cell model. AACR.
Rodriguez M, Figueroa M, Murphy B, Cheng T, Fekry B, Allton K, Barton M, Konopleva M, Mahan K, Chandra J. Effects of diet composition and timing on treatment for FLT3 positive acute myeloid leukemia. American Association for Cancer Research Annual Meeting 2022.
Stitzlein L, Luetzen M, McCabe C, Khosla M, Singh M, Su X, Lu Y, Gumin J, Lang F, Whitehead C, Sebolt-Leopold J, Chandra J. Efficacy of EGFR/PI3K signaling inhibition is enhanced with LSD1 inhibition in glioblastoma stem cell models. Center for Cancer Epigenetics Retreat.
Stitzlein L, Gangadharan A, Grasse L, Espejo A, Singh M, Lu Y, Ezhilarasan R, Gumin J, Sulman E, Lang F, Chandra J. Evaluation of in vitro and in vivo efficacy of pharmacological lysine-specific demethylase 1 (LSD1) inhibitors in glioblastoma stem cell models. Center for Cancer Epigenetics Retreat.
Stitzlein L.M., Adams, J.T., Luetzen, M, McCabe C, Khosla, M, Singh, M, Su,X, Lu, Y, Gumin, J, Lang, F, Whitehead, C, Sebolt-Leopold, J, Chandra J. Investigating the interplay between kinase signaling and lysine-specific demethylase 1 in high-grade gliomas. GSBS Research Day.
Chandra J. Preclinical and clinical strategies for treatment of pediatric malignancies incorporating epigenetic and metabolic vulnerabilities. Indian Science Congress Plenary Session 2023.
Stitzlein L, Adams J, Luetzen M, Singh M, Su X, Lu Y, Ezhilarasan R, Gumin J, Sulman E, Lang F, Monje M, Chandra J. Efficacy of LSD1-Directed Agents is Enhanced with Kinase Signaling Inhibition in Glioblastoma Stem Cells. American Society for Pharmacology and Experimental Therapeutics 2023 Annual Meeting.
Alqahtani S, Figueroa M, Ma H, Chandra J. Investigating the Impact of Smoking Traditional and E-Cigarettes on Acute Myeloid Leukemia Progression. American Society of Hematology.
Miller C, Dujka M, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. Distinct effects of proteasome inhibition by a novel inhibitor in lymphoid cells. EORTC-NCI-AACR Conference on Molecular Targets and Cancer Therapeutics 2004 Annual Meeting.
Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S. Effects of serum from patients with insulin-dependent diabetes mellitus on primary cerebellar granule cells. International Group on Insulin Secretion Symposium 2024: Birth, Life and Death of a Beta-Cell in Type-2 Diabetes.
Alqahtani S, Ma H, Figueroa M, Poche A, Nam D, Chandra J. Understanding the impact of Traditional and E-Cigarette Smoking Metabolites on the Progression of Acute Myeloid Leukemia. American Society of Pediatric Hematology/Oncology 2024 Annual Meeting.
Stitzlein L, Hernandez F, Nam D, Patel K, Impelman K, Poche A, Su X, Gumin J, Sareddy G, Lang F, Chandra J. Enhancing Therapeutic Approaches in High-grade Gliomas: Synergistic Effects of LSD1 and Kinase inhibition. Society of Neurooncology 2024 Annual Meeting.
Patel K, Stitzlein L, Nam D, Lang Frederick, Gumin Joy, Chandra J. Generation and characterization of a glioblastoma stem cell model with acquired resistance to LSD1 inhibition. American Association for Cancer Research 2024 Annual Meeting.
Hernandez F, Stitzlein L, Deokhwa N, Adams J, McCabe C, Monje M, Waranecki P, Hulleman E, Becher O, Chandra J. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. International Symposium on Pediatric Neuro-Oncology 2024.
Nam D, Hernandez F, Stitzlein L, Becher O, Chandra J. Evaluating pharmacological inhibition of LSD1 in models of diffuse midline glioma and effects on immune microenvironment signaling. Society for Neurooncology 2024 Annual Meeting.
Hernandez F, Stitzlein L, Nam D, Adams J, McCabe C, Monje M, Waranecki P, Hulleman E, Becher O, Chandra J. Pharmacological inhibition of LSD1/KDM1A in diffuse midline glioma models and impact on kinase signaling. International Symposium on Pediatric Neuro-Oncology 2024 Annual Meeting.
Alqahtani S, Ma H, Poche A, Estecio M, Lu Y, Figueroa M, Chandra J. Impact of Cigarette Smoke Constituents and Tobacco Metabolites on Acute Leukemia Progression and Therapy. EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Stitzlein L.M., Baig M, Chandra J. Phase I Study of Vorinostat and Temsirolimus in Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma. Society of Neuro-Oncology (SNO).
Chandra J, Mansson E, Gogvadze V, Albertioni F, Orrenius S. Resistance to 2-chlorodeoxyadenosine is mediated by mitochondrial effects associated with apoptosis. Fernstrom Symposium 2000: The Role of Mitochondria in Apoptosis and Neurodegeneration.
Chandra J, Mansson E, Albertioni F, Orrenius S. Resistance to 2-chlorodeoxyadenosine is mediated by mitochondrial effects associated with apoptosis. American Association for Cancer Research 2000 Annual Meeting.
Chandra J, Mow B, Weisberg E, Griffin J, Sausville E, Kaufmann SH. Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on leukemic cells in vitro. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2002 Annual Meeting.
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance. American Society of Hematology 2004 Annual Meeting.
Ruiz S, Krupnik Y, Keating M, Chandra J, McConkey D. Kinetics and Mechanism of Action of Bortezomib in Chronic Lymphocytic Leukemia. Leukemia 2004 Conference.
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann SH. Effects of adaphostin, a novel tyrphostin inhibitor, in diverse models of imatinib mesylate resistance. Annual SPORE Investigator's Workshop 2004 Annual Meeting.
Miller C, Ban K, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia lymphoma cell lines and patient specimens. American Society of Hematology 2005 Annual Meeting.
Miller C, Ruiz S, Neuteboom S, Palladino M, McConkey D, Chandra J. Reactive oxygen species generation and caspase 8 activation are required for apoptosis induction by a novel proteasome inhibitor in lymphoid cells. American Association for Cancer Research 2005 Annual Meeting.
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of ROS production by adaphostin, a kinase inhibitor, on leukemia and myeloma cells. Winter SPORE 2005 Meeting for Hematological Malignancies.
Chandra J and Ban K. Increased Superoxide Levels, HO-1 and Fyn Protein Expression in Bcr/abl Overexpressing Cells: Implications for Adaptation and Survival in an Oxidatively Challenging Environment. American Society of Hematology 2005 Annual Meeting.
Miller C, Dujka M, Ruiz S, Neuteboom S, Palladino M, McConkey M, Chandra J. Preclinical evaluation of NPI-0052, an irreversible proteasome inhibitor, in hematological malignancies. Winter SPORE 2005 Meeting for Hematological Malignancies.

Book Chapters

Figueroa M, Chandra J. Cellular redox status and modifiable behaviors. In: Handbook on Oxidative Stress in Cancer. Springer International Publishing, 2021.
Manton C, Chandra J. Oxidative stress and the proteasome: Mechanisms and therapeutic relevance. In: Resistance to Proteasome Inhibitors in Cancer. Springer International Publishing, 249-274, 2014.
Chandra J, Miller C. Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia. In: New Agents for the Treatment of Acute Lympoblastic Leukemia. Chapter 13. Springer, 273-298, 2011.
Chandra J, Kaufmann SH. Apoptotic pathways in cancer progression and treatment. In: Signal Transduction and Human Health. John Wiley & Sons, Inc, 2003.
Chandra J, Orrenius S. Mitochondria, oxygen metabolism and the regulation of cell death. In: Proceedings from the Third International Conference on Oxygen and Life. Elsevier Sciences, 2002.
Chandra J, Orrenius S. Apoptosis and oxidative stress: Promotion, modulation and abrogation. In: Free Radicals in Chemistry, Biology and Medicine. OICA International UK Limited, 2000.

Less

CV information above last modified March 09, 2026

Joya Chandra, Ph.D.

About Dr. Joya Chandra

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Abstracts

Book Chapters

Patient Reviews

Related Links

Chandra Laboratory

Pediatrics division

Help #EndCancer

Joya Chandra, Ph.D.

About Dr. Joya Chandra

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Chandra Laboratory

Pediatrics division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson